# Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

> **NCT00909727** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 52 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Ivacaftor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00909727
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-11
- **Final completion:** 2011-04
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2012-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00909727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00909727, "Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00909727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*